This video is part of an educational series of four lectures focussed on PCSK9: Outcomes and trials in clinical perspective. In this module, prof. Hovingh discusses how to identify high risk patients for whom PCSK9 inhibitors might be considered.

Educational information

This educational video is the first part of a series called "PCSK9: Outcomes and trials in clinical perspective" that are aimed to give cardiologists in secondary care and other healthcare professionals with an interest in treating patients with cardiovascular disease a well-balanced expert view on the current state of the art about the impact of PCSK9 inhibition on lipids and cardiovascular risk

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Other topics covered in this series

Other lectures part of this educational series are:

• PCSK9 inhibitors: How do they work? - Prof. John Chapman, Pierre and Marie Curie University, Paris, France
• Landmark trials with PCSK9 inhibitors - Prof. Ph. Gabriel Steg, MD, Hôpital Bichat, Paris, France
• Guidelines and the role of non-statin therapies for high risk ASCVD patients - Prof. Wouter Jukema, MD, Leiden University Medical Center , The Netherlands

Faculty

Kees Hovingh, MD - Internist and vascular medicine specialist at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, the Netherlands and visiting professor at Imperial college in London, UK

CME Accreditation

This course is applied for online CME accreditation at EBAC (European Board for Accreitation in Cardiology). Once accredited the CME programme will be available in our CME section

Disclosures

This educational series is funded by an unrestricted educational grant provided by Sanofi-Regeneron.

View slides of prof. Hovingh